Impact of rice based oral rehydration solution on stool output and duration of diarrhoea: meta-analysis of 13 clinical trials.
OBJECTIVE
To define the benefit of rice oral rehydration salts solution in relation to the glucose based World Health Organisation oral rehydration salts solution for treating and preventing dehydration in patients with severe dehydrating diarrhoea.


METHODS
Meta-analysis using data from 13 available randomised trials that compared these two formulations.


METHODS
The studies compared 1367 patients with cholera, severe cholera-like diarrhoea, or acute non-cholera diarrhoea. 668 received the standard WHO solution and 699 the rice based solution.


METHODS
Each trial report was reviewed to determine patient eligibility, the number of patients who were randomised and the number of these excluded from analysis, details of the randomisation procedure, and the precise timing of the outcome measurements.


METHODS
Stool output during the first 24 hours; weighted estimates of the difference in mean stool output between treatments.


RESULTS
The rice solution significantly reduced the rate of stool output during the first 24 hours by 36% (95% confidence interval 28 to 44%) in adults with cholera and by 32% (19 to 45%) in children with cholera. The rate of stool loss in infants and children with acute non-cholera diarrhoea was reduced by only 18% (6 to 30%).


CONCLUSIONS
The benefit of rice oral rehydration salts solution for patients with cholera is sufficiently great to warrant its use in such patients. The benefit is considerably smaller for children with acute, noncholera diarrhoea and should be more precisely defined before its practical value can be judged.
Gore
S M
SM
Medical Research Council, Biostatistics Unit, Cambridge.
Fontaine
O
O
Pierce
N F
NF
D001639:Bicarbonates / Q000627:therapeutic use; D002648:Child; D002771:Cholera / Q000150:complications; D003681:Dehydration / Q000517:prevention & control / Q000628:therapy*; D003967:Diarrhea / Q000209:etiology / Q000628:therapy*; D005440:Fluid Therapy; D005947:Glucose / Q000627:therapeutic use; D006801:Humans; D015201:Meta-Analysis as Topic; D012275:Oryza; D011189:Potassium Chloride / Q000627:therapeutic use; D015532:Rehydration Solutions / Q000627:therapeutic use*; D012965:Sodium Chloride / Q000627:therapeutic use; D013997:Time Factors
D001639:Bicarbonates; D015532:Rehydration Solutions; C044142:World Health Organization oral rehydration solution; D012965:Sodium Chloride; D011189:Potassium Chloride; D005947:Glucose